'Vanishing' prostate cancer in radical prostatectomy specimens: Incidence and long-term follow-up in 38 cases

BJU International

Volumn 94, Issue 1, 2004, Pages 57-58

  Bostwick, David G ^a,b   Bostwick, Kathleen C ^a  

^a MAYO CLINIC   (United States)

^b BOSTWICK LABORATORIES   (United States)

Author keywords

Incidence; Prognosis; Prostate cancer; Radical prostatectomy; Tissue sampling; Vanishing cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; REVIEW; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

ADULT; AGED; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; ORGAN SIZE; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 3242805971     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04900.x     Document Type: Review

References (11)

1. DiGiuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol 1997; 21: 174-8
2. Bostwick DG, Montironi R. Evaluating radical prostatectomy specimens. Therapeutic and prognostic importance. Virchows Arch 1997; 430: 1-16
3. Goldstein NS, Begin LR, Grody WW, Novak JM, Qian J, Bostwick DG. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the 'vanishing cancer phenomenon'. Am J Surg Pathol 1995; 19: 1002-9
4. Kronz JD, Westra WH, Epstein JI. Mandatory second opinion surgical pathology at a large reference hospital. Cancer, 1999; 86: 2426-35
5. Bostwick D, Cheng L. Overdiagnosis of prostatic adenocarcinoma. Sem Urol Oncol 1999; 17: 199-205
6. Sakr WA, Grignon DJ, Prostate. Practice parameters, pathologic staging, and handling radical prostatectomy specimens. Urol Clin North Am 1999; 26: 453-63
7. Sehdev AE, Pan CC, Epstein J. I. Comparative analysis of sampling methods for grossing radical prostatectomy specimens performed for nonpalpable (state T1c) prostatic adenocarcinoma. Hum Pathol 2001; 32: 494-9
8. Hollenbeck BK, Bassily N, Wei JT et al. A. Whole mounted radical prostatectomy specimens do not increase detection of adverse pathological features. J Urol 2000; 164: 1583-6
9. True LD. Surgical pathology examination of the prostate gland. Practice survey by American Society of Clinical Pathologists. Am J Clin Pathol 1994; 102: 572-9
10. Ghavamian R, Blute ML, Bergstrahl EJ, Slezak J, Zincke H. Comparison of clinical nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology 1999; 54: 105-10
11. Blute ML, Bostwick DG, Seay TM et al. Pathologic classification of prostate cancer: the impact of margin status. Cancer 1998; 82: 902-8